BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 28466157)

  • 1. Liquid biopsy: unlocking the potentials of cell-free DNA.
    Chu D; Park BH
    Virchows Arch; 2017 Aug; 471(2):147-154. PubMed ID: 28466157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of circulating tumor DNA (ctDNA) by digital droplet polymerase chain reaction (dd-PCR) in liquid biopsies.
    Valpione S; Campana L
    Methods Enzymol; 2019; 629():1-15. PubMed ID: 31727235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enrichment and Analysis of ctDNA.
    Gilson P
    Recent Results Cancer Res; 2020; 215():181-211. PubMed ID: 31605230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Interest of Circulating Tumor DNA in Oncology.
    Franczak C; Filhine-Tressarieu P; Broséus J; Gilson P; Merlin JL; Harlé A
    Arch Med Res; 2018 Jul; 49(5):297-305. PubMed ID: 30414710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
    Cheng ML; Pectasides E; Hanna GJ; Parsons HA; Choudhury AD; Oxnard GR
    CA Cancer J Clin; 2021 Mar; 71(2):176-190. PubMed ID: 33165928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients.
    Zavarykina TM; Lomskova PK; Pronina IV; Khokhlova SV; Stenina MB; Sukhikh GT
    Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic Treatment Stratification Using ctDNA.
    Vidal J; Taus A; Montagut C
    Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioinformatics Analysis for Cell-Free Tumor DNA Sequencing Data.
    Chen S; Liu M; Zhou Y
    Methods Mol Biol; 2018; 1754():67-95. PubMed ID: 29536438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Circulating Tumor DNA in Renal Cell Carcinoma.
    Bergerot PG; Hahn AW; Bergerot CD; Jones J; Pal SK
    Curr Treat Options Oncol; 2018 Feb; 19(2):10. PubMed ID: 29464405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer.
    Pellini B; Szymanski J; Chin RI; Jones PA; Chaudhuri AA
    Thorac Surg Clin; 2020 May; 30(2):165-177. PubMed ID: 32327175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
    Vymetalkova V; Cervena K; Bartu L; Vodicka P
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
    Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
    Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual.
    Koessler T; Addeo A; Nouspikel T
    Adv Clin Chem; 2019; 89():131-188. PubMed ID: 30797468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer.
    El Achi H; Khoury JD; Loghavi S
    Curr Hematol Malig Rep; 2019 Oct; 14(5):358-367. PubMed ID: 31346903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine.
    Rossi G; Ignatiadis M
    Cancer Res; 2019 Jun; 79(11):2798-2804. PubMed ID: 31109952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing in liquid biopsy: cancer screening and early detection.
    Chen M; Zhao H
    Hum Genomics; 2019 Aug; 13(1):34. PubMed ID: 31370908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA.
    Barlebo Ahlborn L; Østrup O
    APMIS; 2019 May; 127(5):329-336. PubMed ID: 30784124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology.
    Ponti G; Manfredini M; Tomasi A
    Crit Rev Oncol Hematol; 2019 Sep; 141():36-42. PubMed ID: 31212145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.